<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Chemokine (C-X-C motif) ligand 12 (CXCL12) (also known as stromal cell-derived factor-1 [SDF-1]-alpha) is a homeostatic chemokine with multiple roles in cell homing, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumour metastasis</z:e>, <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and tissue regeneration after <z:hpo ids='HP_0011009'>acute</z:hpo> injuries </plain></SENT>
<SENT sid="1" pm="."><plain>However, its role in <z:hpo ids='HP_0011010'>chronic</z:hpo> diseases remains poorly defined, e.g. in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0268731" disease_type="Disease or Syndrome" abbrv="">glomerular diseases</z:e> like diabetic <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesised that CXCL12 may have a functional role during the evolution of diabetic <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo>, either by assisting glomerular repair or by supporting the maladaptive tissue remodelling in response to <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and glomerular hyperfiltration </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: To define the functional role of CXCL12 in the progression of <z:e sem="disease" ids="C0268731" disease_type="Disease or Syndrome" abbrv="">glomerular disease</z:e>, we used the CXCL12-specific inhibitor NOX-A12, an L: -enantiomeric <z:chebi fb="40" ids="33697">RNA</z:chebi> oligonucleotide (Spiegelmer) </plain></SENT>
<SENT sid="4" pm="."><plain>A mouse model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (db/db mice) was used </plain></SENT>
<SENT sid="5" pm="."><plain>Male db/db mice, uni-nephrectomised at 6 weeks of age, received subcutaneous injections with a PEGylated form of NOX-A12, non-functional control Spiegelmer or vehicle on alternate days from 4 to 6 months of age </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Immunostaining localised renal CXCL12 production to glomerular podocytes in db/db mice with early or advanced diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>CXCL12 inhibition significantly reduced the degree of <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo>, increased the number of podocytes, prevented the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:mp ids='MP_0002871'>albuminuria</z:mp> and maintained the peritubular vasculature without affecting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels, body weight or glomerular macrophage infiltration </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: We conclude that podocytes produce CXCL12, which contributes to <z:hpo ids='HP_0000093'>proteinuria</z:hpo> and <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo> in our mouse model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>This novel pathomechanism provides the first evidence that CXCL12 could be a therapeutic target in (diabetic) <z:hpo ids='HP_0000096'>glomerulosclerosis</z:hpo> </plain></SENT>
</text></document>